Alzheimer’s drug enters major clinical trial

As reported on A commonly prescribed diabetes drug may reverse the symptoms of Alzheimer’s so has now entered into a major clinical trial.

The initial research, which was funded by the Alzheimer’s Society, claims the drug liraglutide may be able to reverse some of the damage caused in the later stages of the disease, such as memory loss and the build up of plaques on the brain.

Liraglutide is currently used by diabetes sufferers to help  stimulate insulin, but research has shown it also has the ability to pass through the blood brain barrier and have a protective effect on brain cells.

The Alzheimer Society’s Drug Discovery programme repurposes existing drugs for use in dementia treatment. Early research showed the potential in early stage Alzheimer’s leading to a major clinical trial, led by the Imperial College of London. With the recruitment of patients beginning in the next few weeks and if successful liraglutide will be the first new dementia treatment in ten years!

To read this article in full click here

If you would like to search for a job in Drug Discover click here now


  Clinical Trials jobs at CK Clinical

Posted in: Industry News, News
CK Logo in place of featured image